Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index; 16 of the 23 sources its claims cite were checked for support.

ICR suckling mouse model of Zika virus infection for disease modeling and drug validation

Open access

Abstract

BACKGROUND: Zika virus (ZIKV) infection causes diseases ranging from acute self-limiting febrile illness to life-threatening Guillain-Barré Syndrome and other neurological disorders in adults. Cumulative evidence suggests an association between ZIKV infection and microcephaly in newborn infants. Given the host-range restrictions of the virus, a susceptible animal model infected by ZIKV must be developed for evaluation of vaccines and antivirals. In this study, we propose a convenient mouse model for analysis of neurological disorders caused by ZIKV. METHODOLOGY: Six-day-old immunocompetent ICR suckling mice were used in the experiment. Different inoculum virus concentrations, challenge routes, and challenge times were assessed. Viremic dissemination was determined in the liver, spleen, kidney, and brain through Western blot assay, plaque assay, absolute quantification real-time PCR, and histological observation. Azithromycin, a well-characterized anti-ZIKV compound, was used to evaluate the ICR suckling mouse model for antiviral testing. CONCLUSIONS: Signs of illness and neurological disease and high mortality rate were observed in mice injected with ZIKV intracerebrally (102 to 105) and intraperitoneally (103 to 105). Viremic dissemination was observed in the liver, spleen, kidney, and brain. ZIKV transmitted, rapid replicated, and induced monocyte infiltration into the brain approximately 5 to 6 days post inoculum. Azithromycin conferred protection against ZIKV-caused neurological and life-threatening diseases. The developed model of ZIKV infection and disease can be used for screening drugs against ZIKV and discovering the underlying mechanism of ZIKV pathogenesis.

Overview

CoChat Summary

TL;DR

Six-day-old immunocompetent ICR suckling mice support Zika virus (ZIKV) infection by intracerebral and intraperitoneal routes, showing high mortality, systemic viral dissemination, brain monocyte infiltration, and neurological disease. Azithromycin protected against lethal ZIKV infection and reduced brain viral RNA and titer, supporting this model for anti-ZIKV drug testing.

Key findings

  • Intracerebral (i.c.) injection of 10²–10⁵ PFU ZIKV caused 80%–100% mortality at 5–7 days post infection (dpi); intraperitoneal (i.p.) injection of 10³–10⁵ PFU caused high mortality about 1 day later, while 10² PFU i.p. led to 20% mortality.
  • ZIKV RNA in brain ranged from 10⁹–10¹⁰ copies/μg RNA after i.c. injection and 10⁶–10⁹ copies/μg RNA after i.p. injection; brain viral titer was 10⁷–10⁹ PFU/g tissue (i.c.) versus 10⁴–10⁸ PFU/g tissue (i.p.). ZIKV RNA was also detected in liver (10⁵–10⁸ copies/μg RNA), spleen (10⁴–10⁷), and kidney (10⁵–10⁷).
  • Monocyte infiltration into the brain was observed around 5–6 days post inoculum, coinciding with ZIKV detection in brain tissue.
  • Azithromycin at 1 and 10 mg/kg protected 80% and 100% of mice, respectively, from life-threatening ZIKV infection; it reduced ZIKV RNA copies by 1.58±0.27 and 2.52±0.25 log10 and viral titer by 0.81±0.18 and 1.55±0.16 log10, respectively, compared with untreated ZIKV-infected mice.

Methods

  • Six-day-old ICR suckling mice weighing 3.5–4 g were infected with ZIKV strain MR-766 at 10²–10⁵ PFU by i.c. or i.p. injection; heat-inactivated ZIKV served as mock control. Survival, clinical score, and body weight were recorded daily, with sacrifice at 8 dpi in initial studies.
  • Brain, liver, spleen, and kidney tissues were analyzed by Western blot with anti-ZIKV NS2B antibody, absolute quantification real-time PCR targeting ZIKV NS5, plaque assay in Vero cells, H&E staining, and immunohistochemistry with anti-Ly6C antibody quantified by ImageJ.
  • For antiviral testing, mice received i.p. 10⁴ PFU ZIKV and azithromycin (1 or 10 mg/kg) at 1, 3, and 5 dpi; controls included heat-inactivated ZIKV and azithromycin-only groups. Data were analyzed by Student’s t-test using GraphPad Prism 6 and expressed as mean ± SD of at least three independent experiments.

Limitations

  • The paper states that the age of the suckling mice creates limitations: viremia in the blood was hard to collect and process, and studies of vertical transmission were not available.
  • Evident from the text: experimental groups used small sample sizes (n = 3–5), observation periods were short (7–8 dpi), and only ZIKV strain MR-766 was tested.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pntd.0006848

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Survival rate, body weight, and clinical score of ICR suckling mice infected with ZIKV by i.p. and i.c. injection. Six-day-old ICR suckling mice received 102 to 105 PFU ZIKV by i.c. (n = 5) or i.p. (n = 5) injection. (A–D) Survival rate, (E–H) clinical score, and (I–L) body weight recorded every day. Mice were sacrificed at 8 dpi. Disease severity was scored as follows: 0: healthy, 1: body weight loss and ruffled fur, 2: lethargy and unsteady gait, 3: kinetic tremors and severe ataxia, 4: paralysis, and 5: death.
Fig 1 Survival rate, body weight, and clinical score of ICR suckling mice infected with ZIKV by i.p. and i.c. injection. Six-day-old ICR suckling mice received 102 to 105 PFU ZIKV by i.c. (n = 5) or i.p. (n = 5) injection. (A–D) Survival rate, (E–H) clinical score, and (I–L) body weight recorded every day. Mice were sacrificed at 8 dpi. Disease severity was scored as follows: 0: healthy, 1: body weight loss and ruffled fur, 2: lethargy and unsteady gait, 3: kinetic tremors and severe ataxia, 4: paralysis, and 5: death.CC BY · PubMed Central
Fig 2 ZIKV replication in different organs of mice that underwent i.p. and i.c. injection of various doses of ZIKV. Six-day-old ICR suckling mice received 102 to 105 PFU ZIKV by i.c. or i.p. injection. Mice were sacrificed, and the brain, liver, spleen, and kidney tissues were collected to analyze ZIKV RNA replication and protein synthesis. (A and B) ZIKV protein synthesis in the brain tissues of mice that received ZIKV by (A) i.c. or (B) i.p. as detected by Western blot analysis with anti-ZIKV NS2B antibody. GAPDH served as equal loading control. (C and D) ZIKV RNA levels in the brain tissue of mice that received ZIKV by (C) i.c. or (D) i.p. as determined by qRT-PCR analysis. The ZIKV RNA level was normalized by the cellular gapdh mRNA level. (E and F) ZIKV viral titer in the brain tissue of mice that received ZIKV by (E) i.c. or (F) i.p. as determined by plaque forming assay. (G and H) ZIKV RNA levels in the liver tissue of mice that received ZIKV by (G) i.c. or (H) i.p. as determined by qRT-PCR analysis. (I and J) ZIKV RNA levels in the spleen tissue of mice that received ZIKV by (I) i.c. or (J) i.p. as determined by qRT-PCR analysis. (K and L) ZIKV RNA levels in the kidney tissue of mice that received ZIKV by (K) i.c. or (L) i.p. as determined by qRT-PCR analysis.
Fig 2 ZIKV replication in different organs of mice that underwent i.p. and i.c. injection of various doses of ZIKV. Six-day-old ICR suckling mice received 102 to 105 PFU ZIKV by i.c. or i.p. injection. Mice were sacrificed, and the brain, liver, spleen, and kidney tissues were collected to analyze ZIKV RNA replication and protein synthesis. (A and B) ZIKV protein synthesis in the brain tissues of mice that received ZIKV by (A) i.c. or (B) i.p. as detected by Western blot analysis with anti-ZIKV NS2B antibody. GAPDH served as equal loading control. (C and D) ZIKV RNA levels in the brain tissue of mice that received ZIKV by (C) i.c. or (D) i.p. as determined by qRT-PCR analysis. The ZIKV RNA level was normalized by the cellular gapdh mRNA level. (E and F) ZIKV viral titer in the brain tissue of mice that received ZIKV by (E) i.c. or (F) i.p. as determined by plaque forming assay. (G and H) ZIKV RNA levels in the liver tissue of mice that received ZIKV by (G) i.c. or (H) i.p. as determined by qRT-PCR analysis. (I and J) ZIKV RNA levels in the spleen tissue of mice that received ZIKV by (I) i.c. or (J) i.p. as determined by qRT-PCR analysis. (K and L) ZIKV RNA levels in the kidney tissue of mice that received ZIKV by (K) i.c. or (L) i.p. as determined by qRT-PCR analysis.CC BY · PubMed Central
Fig 3 Monocyte infiltration in the brain of ICR suckling mice that received i.c. injection of various doses of ZIKV. Six-day-old ICR suckling mice received 102 to 105 PFU ZIKV by i.c. or i.p. injection. Mice were sacrificed, and the brain tissues of mice that received ZIKV by (A) i.c. or (B) i.p. were collected and subjected to hematoxylin and eosin staining. The biopsy specimens were examined by microscope. (C, D) The quantitation of monocyte infiltration by IHC assay.
Fig 3 Monocyte infiltration in the brain of ICR suckling mice that received i.c. injection of various doses of ZIKV. Six-day-old ICR suckling mice received 102 to 105 PFU ZIKV by i.c. or i.p. injection. Mice were sacrificed, and the brain tissues of mice that received ZIKV by (A) i.c. or (B) i.p. were collected and subjected to hematoxylin and eosin staining. The biopsy specimens were examined by microscope. (C, D) The quantitation of monocyte infiltration by IHC assay.CC BY · PubMed Central
Fig 4 ZIKV replication in the brain of mice i.p. injected with 104 PFU ZIKV. Six-day-old ICR suckling mice received 104 PFU ZIKV by i.p. injection, and brain tissues were collected every day (n = 3) for analysis of ZIKV (A) protein synthesis, (B) RNA replication, (C) viral titer, and (D) monocyte infiltration. (E) The quantitation of monocyte infiltration by IHC assay. *P < 0.05; **P<0.01.
Fig 4 ZIKV replication in the brain of mice i.p. injected with 104 PFU ZIKV. Six-day-old ICR suckling mice received 104 PFU ZIKV by i.p. injection, and brain tissues were collected every day (n = 3) for analysis of ZIKV (A) protein synthesis, (B) RNA replication, (C) viral titer, and (D) monocyte infiltration. (E) The quantitation of monocyte infiltration by IHC assay. *P < 0.05; **P<0.01.CC BY · PubMed Central
Fig 5 Survival rate, body weight, and clinical score in ZIKV-infected ICR suckling mice treated with Az. Six-day-old ICR suckling mice were divided into four groups. Group 1 received heat inactivated ZIKV; group 2 received 10 mg/kg of Az but without ZIKV infection (Az 10 mg/kg); group 3 received activated ZIKV and saline treatment; group 4 received activated ZIKV and 1 mg/kg Az; and group 5 received activated ZIKV and 10 mg/kg Az. (A) Survival rate, (B) clinical score, and (C) body weight were recorded every day. Mice were sacrificed at 7 dpi. Disease severity was scored as follows: 0: healthy, 1: body weight loss and ruffled fur, 2: lethargy and unsteady gait, 3: kinetic tremors and severe ataxia, 4: paralysis, and 5: death. *P < 0.05.
Fig 5 Survival rate, body weight, and clinical score in ZIKV-infected ICR suckling mice treated with Az. Six-day-old ICR suckling mice were divided into four groups. Group 1 received heat inactivated ZIKV; group 2 received 10 mg/kg of Az but without ZIKV infection (Az 10 mg/kg); group 3 received activated ZIKV and saline treatment; group 4 received activated ZIKV and 1 mg/kg Az; and group 5 received activated ZIKV and 10 mg/kg Az. (A) Survival rate, (B) clinical score, and (C) body weight were recorded every day. Mice were sacrificed at 7 dpi. Disease severity was scored as follows: 0: healthy, 1: body weight loss and ruffled fur, 2: lethargy and unsteady gait, 3: kinetic tremors and severe ataxia, 4: paralysis, and 5: death. *P < 0.05.CC BY · PubMed Central
Fig 6 ZIKV replication and ZIKV-induced monocyte infiltration were suppressed by Az treatment in ZIKV-infected ICR suckling mice. Six-day-old ICR suckling mice were divided into four groups. Group 1 received heat inactivated ZIKV; group 2 received 10 mg/kg of Az but without ZIKV infection (Az 10 mg/kg); group 3 received activated ZIKV and saline treatment; group 4 received activated ZIKV and 1 mg/kg Az; and group 5 received activated ZIKV and 10 mg/kg Az. Mice were sacrificed at 7 dpi, and the brain tissues were collected for analysis of (A) ZIKV RNA replication, (B) viral titer, and (C) monocyte infiltration. (D) The quantitation of monocyte infiltration. *P < 0.05.
Fig 6 ZIKV replication and ZIKV-induced monocyte infiltration were suppressed by Az treatment in ZIKV-infected ICR suckling mice. Six-day-old ICR suckling mice were divided into four groups. Group 1 received heat inactivated ZIKV; group 2 received 10 mg/kg of Az but without ZIKV infection (Az 10 mg/kg); group 3 received activated ZIKV and saline treatment; group 4 received activated ZIKV and 1 mg/kg Az; and group 5 received activated ZIKV and 10 mg/kg Az. Mice were sacrificed at 7 dpi, and the brain tissues were collected for analysis of (A) ZIKV RNA replication, (B) viral titer, and (C) monocyte infiltration. (D) The quantitation of monocyte infiltration. *P < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 2 Not valid · 3 Not checked · 43 Own results and interpretations

26 more claims

Create a free account to see all 55 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 17
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 54 references

Cited by

See all 35

Metadata

Authors
Wu, Y.-H., Tseng, C.-K., Lin, C.-K., Wei, C.-K., Lee, J.-C., & Young, K.-C.
Affiliations
  • National Cheng Kung University (TW)
  • National Sun Yat-sen University (TW)
  • Kaohsiung Medical University (TW)
Corresponding author
  • Lee, Jin-Ching
  • Young, Kung-Chia
Venue
PLoS Neglected Tropical Diseases
Published
2018-10-24
Volume
12
Issue
10
Pages
e0006848
ISSN
  • 1935-2727 (ISSN-L)
  • 1935-2735
OpenAlex
W2898365945
Cited by
35
References
54
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 6 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 6
FWCI
4.76
Type
journal article
Language
en
Open access
Locations
  • PLoS neglected tropical diseases (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Ministry of Science and Technology, Taiwan ((MOST104-2320-B-037-025-MY3, MOST 107-2311-B-037 -005 -MY3)
  • Kaohsiung Medical University (KMU-DK107011)
  • National Sun Yat-sen University (NSYSU-KMU 107-I003)
  • Industry-University Service Research Project (S106002)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Mosquito-borne diseases and control
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Vectors
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Outbreaks Research
Keywords
Zika virus, suckling mouse model, neurological disorders, Guillain-Barré syndrome, microcephaly, viremia, azithromycin, antiviral drug screening, vaccine evaluation, viral pathogenesis, intracerebral injection, intraperitoneal inoculation
MeSH terms
Zika Virus Infection, Zika Virus, Animals, Animal Structures, Animals, Newborn, Antiviral Agents, Disease Models, Animal, Drug Evaluation, Preclinical, Histocytochemistry, Mice, Inbred ICR, Viral Plaque Assay, Viral Load, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ICR suckling mouse model of Zika virus infection for disease modeling and drug validation. https://app.cochat.ai/papers/10.1371/journal.pntd.0006848
The paper
Wu, Y.-H., Tseng, C.-K., Lin, C.-K., Wei, C.-K., Lee, J.-C., & Young, K.-C. (2018). ICR suckling mouse model of Zika virus infection for disease modeling and drug validation. PLoS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0006848

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.